Satomi et al. investigated MTAP immunostaining as a surrogate marker for CDKN2A loss in 178 diffuse gliomas (77 astrocytoma IDH-mutant, 13 oligodendrogliomas, and 88 glioblastomas, IDH-wildtype) [2,14]. Here, MTAP is linked to astrocytoma (excluding glioblastoma).